Ciprofloxacin for Treating Infections from Resistant Bacteria
Author Information
Author(s): Rubiñan Pablo, Viñado Belén, Fernández-Hidalgo Nuria, Larrosa Nieves, Sempere Abiu, Campany David, Rodríguez-Pardo Dolors, González-López Juan José, Nuvials Xavier, del Barrio-Tofiño Ester, Escolà-Vergé Laura, Los-Arcos Ibai
Primary Institution: Vall d’Hebron University Hospital, Barcelona, Spain
Hypothesis
Can ciprofloxacin be an effective treatment for infections caused by carbapenemase-producing Gram-negative bacteria?
Conclusion
Ciprofloxacin monotherapy may be a viable treatment option for selected patients with ciprofloxacin-susceptible infections caused by carbapenemase-producing Gram-negative bacteria.
Supporting Evidence
- 79% of the patients were men.
- The median age of patients was 74 years.
- Only one patient experienced clinical failure at day 14.
- There was no 30-day mortality among the patients.
- Two patients had microbiological recurrence at day 90.
- 32% of patients had positive blood cultures.
- The median duration of ciprofloxacin treatment was 14 days.
Takeaway
This study looked at whether ciprofloxacin could help people with tough infections from certain bacteria. It found that it worked well for most patients.
Methodology
A retrospective single-centre study analyzing the clinical outcomes of adult patients treated with ciprofloxacin for carbapenemase-producing Gram-negative bacteria infections.
Potential Biases
Potential bias due to the single-centre design and retrospective nature of the study.
Limitations
The study's retrospective design and lack of a control group limit the generalizability of the findings.
Participant Demographics
The median age of participants was 74 years, with 79% being men and 42% immunosuppressed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website